skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 225  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Material Type:
Article 		Add to My Research

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Journal of the American College of Cardiology, 2018-04, Vol.71 (16), p.1755-1764 [Peer Reviewed Journal]

2018 American College of Cardiology Foundation ;Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Apr 24, 2018 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2018.02.037 ;PMID: 29567210

Full text available

Citations Cited by
2
Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy
Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy
Material Type:
Article 		Add to My Research

Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy

Immunotherapy, 2017-01, Vol.9 (2), p.115-121 [Peer Reviewed Journal]

Future Medicine Ltd ;Copyright Future Medicine Ltd Feb 2017 ;ISSN: 1750-743X ;EISSN: 1750-7448 ;DOI: 10.2217/imt-2016-0138 ;PMID: 28128709

Full text available

Citations Cited by
3
Current Melanoma Treatments: Where Do We Stand?
Current Melanoma Treatments: Where Do We Stand?
Material Type:
Article 		Add to My Research

Current Melanoma Treatments: Where Do We Stand?

Cancers, 2021-01, Vol.13 (2), p.221 [Peer Reviewed Journal]

2021. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13020221 ;PMID: 33435389

Full text available

Citations Cited by
4
C-reactive protein as an early marker of immune-related adverse events
C-reactive protein as an early marker of immune-related adverse events
Material Type:
Article 		Add to My Research

C-reactive protein as an early marker of immune-related adverse events

Journal of cancer research and clinical oncology, 2019-10, Vol.145 (10), p.2625-2631 [Peer Reviewed Journal]

Springer-Verlag GmbH Germany, part of Springer Nature 2019 ;Journal of Cancer Research and Clinical Oncology is a copyright of Springer, (2019). All Rights Reserved. ;ISSN: 0171-5216 ;EISSN: 1432-1335 ;DOI: 10.1007/s00432-019-03002-1 ;PMID: 31492984

Full text available

Citations Cited by
5
Therapy preferences in melanoma treatment--willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls
Therapy preferences in melanoma treatment--willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls
Material Type:
Article 		Add to My Research

Therapy preferences in melanoma treatment--willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls

PloS one, 2014-11, Vol.9 (11), p.e111237 [Peer Reviewed Journal]

COPYRIGHT 2014 Public Library of Science ;COPYRIGHT 2014 Public Library of Science ;2014 Krammer, Heinzerling. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2014 Krammer, Heinzerling 2014 Krammer, Heinzerling ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0111237 ;PMID: 25369124

Full text available

Citations Cited by
6
Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis
Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis
Material Type:
Article 		Add to My Research

Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis

Journal of the American College of Cardiology, 2020-02, Vol.75 (5), p.467-478 [Peer Reviewed Journal]

2020 ;Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved. ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2019.11.049 ;PMID: 32029128

Full text available

Citations Cited by
7
Inflammatory markers in autoimmunity induced by checkpoint inhibitors
Inflammatory markers in autoimmunity induced by checkpoint inhibitors
Material Type:
Article 		Add to My Research

Inflammatory markers in autoimmunity induced by checkpoint inhibitors

Journal of cancer research and clinical oncology, 2021-06, Vol.147 (6), p.1623-1630 [Peer Reviewed Journal]

The Author(s) 2021 ;COPYRIGHT 2021 Springer ;The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0171-5216 ;EISSN: 1432-1335 ;DOI: 10.1007/s00432-021-03550-5 ;PMID: 33837821

Full text available

Citations Cited by
8
Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis
Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis
Material Type:
Article 		Add to My Research

Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis

Journal of the American College of Cardiology, 2021-03, Vol.77 (12), p.1503-1516 [Peer Reviewed Journal]

2021 American College of Cardiology Foundation ;Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;COPYRIGHT 2021 Elsevier B.V. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2021.01.050 ;PMID: 33766256

Full text available

Citations Cited by
9
The skin prick test – European standards
The skin prick test – European standards
Material Type:
Article 		Add to My Research

The skin prick test – European standards

Clinical and translational allergy, 2013-02, Vol.3 (1), p.3-n/a [Peer Reviewed Journal]

2020 The Authors. Clinical and Translational Allergy published by John Wiley and Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology ;COPYRIGHT 2013 BioMed Central Ltd. ;COPYRIGHT 2013 BioMed Central Ltd. ;Copyright ©2013 Heinzerling et al.; licensee BioMed Central Ltd. 2013 Heinzerling et al.; licensee BioMed Central Ltd. ;ISSN: 2045-7022 ;EISSN: 2045-7022 ;DOI: 10.1186/2045-7022-3-3 ;PMID: 23369181

Full text available

Citations Cited by
10
The Role of Immune Checkpoint Blockade in Uveal Melanoma
The Role of Immune Checkpoint Blockade in Uveal Melanoma
Material Type:
Article 		Add to My Research

The Role of Immune Checkpoint Blockade in Uveal Melanoma

International journal of molecular sciences, 2020-01, Vol.21 (3), p.879 [Peer Reviewed Journal]

2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the authors. 2020 ;ISSN: 1422-0067 ;ISSN: 1661-6596 ;EISSN: 1422-0067 ;DOI: 10.3390/ijms21030879 ;PMID: 32013269

Full text available

Citations Cited by
11
Non-professional phagocytosis: a general feature of normal tissue cells
Non-professional phagocytosis: a general feature of normal tissue cells
Material Type:
Article 		Add to My Research

Non-professional phagocytosis: a general feature of normal tissue cells

Scientific reports, 2019-08, Vol.9 (1), p.11875-11875, Article 11875 [Peer Reviewed Journal]

The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-019-48370-3 ;PMID: 31417141

Full text available

Citations Cited by
12
Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation
Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation
Material Type:
Article 		Add to My Research

Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation

Frontiers in oncology, 2021-10, Vol.11, p.740002-740002 [Peer Reviewed Journal]

Copyright © 2021 Jost, Heinzerling, Fietkau, Hecht and Distel. ;Copyright © 2021 Jost, Heinzerling, Fietkau, Hecht and Distel 2021 Jost, Heinzerling, Fietkau, Hecht and Distel ;ISSN: 2234-943X ;EISSN: 2234-943X ;DOI: 10.3389/fonc.2021.740002 ;PMID: 34722291

Full text available

Citations Cited by
13
Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential
Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential
Material Type:
Article 		Add to My Research

Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential

International journal of molecular sciences, 2020-12, Vol.21 (23), p.9321 [Peer Reviewed Journal]

2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the authors. 2020 ;ISSN: 1422-0067 ;ISSN: 1661-6596 ;EISSN: 1422-0067 ;DOI: 10.3390/ijms21239321 ;PMID: 33297429

Full text available

Citations Cited by
14
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
Material Type:
Article 		Add to My Research

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

The Lancet (British edition), 2023-09, Vol.402 (10404), p.798-808 [Peer Reviewed Journal]

2023 Elsevier Ltd ;Copyright © 2023 Elsevier Ltd. All rights reserved. ;2023. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(23)00769-9 ;PMID: 37451295

Full text available

Citations Cited by
15
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Material Type:
Article 		Add to My Research

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management

ESMO open, 2019, Vol.4 (3), p.e000491-e000491, Article e000491 [Peer Reviewed Journal]

Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. ;2019 © 2019 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology. ;Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. 2019 ;ISSN: 2059-7029 ;EISSN: 2059-7029 ;DOI: 10.1136/esmoopen-2019-000491 ;PMID: 31231568

Full text available

Citations Cited by
16
PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts
PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts
Material Type:
Article 		Add to My Research

PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts

BMC cancer, 2020-08, Vol.20 (1), p.775-10, Article 775 [Peer Reviewed Journal]

COPYRIGHT 2020 BioMed Central Ltd. ;COPYRIGHT 2020 BioMed Central Ltd. ;2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-020-07190-9 ;PMID: 32811446

Full text available

Citations Cited by
17
Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation
Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation
Material Type:
Article 		Add to My Research

Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation

Cancers, 2021-05, Vol.13 (10), p.2498 [Peer Reviewed Journal]

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13102498 ;PMID: 34065419

Full text available

Citations Cited by
18
TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients
TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients
Material Type:
Article 		Add to My Research

TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients

BMC cancer, 2023-11, Vol.23 (1), p.1-1160, Article 1160 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2023 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-023-11551-5 ;PMID: 38017389

Full text available

Citations Cited by
19
Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma
Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma
Material Type:
Article 		Add to My Research

Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma

BMC cancer, 2019-03, Vol.19 (1), p.207-207, Article 207 [Peer Reviewed Journal]

COPYRIGHT 2019 BioMed Central Ltd. ;COPYRIGHT 2019 BioMed Central Ltd. ;Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-019-5384-z ;PMID: 30845981

Full text available

Citations Cited by
20
Therapy preferences in melanoma treatment—Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease
Therapy preferences in melanoma treatment—Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease
Material Type:
Article 		Add to My Research

Therapy preferences in melanoma treatment—Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease

Cancer medicine (Malden, MA), 2020-09, Vol.9 (17), p.6132-6140 [Peer Reviewed Journal]

2020 The Authors. published by John Wiley & Sons Ltd. ;2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. ;2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2045-7634 ;EISSN: 2045-7634 ;DOI: 10.1002/cam4.3191 ;PMID: 32649807

Full text available

Citations Cited by

Results 1 - 20 of 225  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (139)

Refine My Results

Creation Date 

From To
Refine
  1. Before 2002  (8)
  2. 2002 To 2005  (20)
  3. 2006 To 2013  (20)
  4. 2014 To 2018  (53)
  5. After 2018  (119)
  6. More options open sub menu

Language 

  1. English  (220)
  2. German  (17)
  3. Japanese  (16)
  4. French  (13)
  5. Spanish  (1)
  6. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait